Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About
2026-07-30 20:15
•Prosper Junior Bakiny •The Motley Fool
•••• ••• Axe Cap view
Why Johnson & Johnson’s Legal Settlement Matters More Than Its Robot
JNJ’s strong run is supported by legal clarity and steady dividends, not just shiny new tech.
Johnson & Johnson’s recent FDA clearance for its Ottava surgical robot and its 64th straight dividend hike grab headlines, but what should really catch investors’ attention is the proposed $5.5 billion talc settlement. This move could finally remove a huge legal cloud that’s been dragging on the share price for years. The stock is up 28% this year, signaling renewed confidence. For South Africans, the direct opportunity is limited, but JNJ’s resilience does make the USD/ZAR an interesting proxy here — a stable giant like JNJ supports dollar strength, which in turn pressures the rand. While high dividend payments and a strong drug pipeline are welcome, watch out: if the settlement falls through or if innovation disappoints, gains could roll back. For JSE investors, there’s no perfect local copycat, but the defensive qualities of large banks like Standard Bank or FirstRand, which also benefit from dollar inflows, could partially mirror JNJ’s steady appeal. this is just our opinion and not financial advice
For exposure to global resilience, buy USD/ZAR hedge positions while trimming rand-sensitive cyclicals. Avoid speculative JSE stocks overly reliant on domestic demand for now.
- Johnson & Johnson (JNJ)
- USD/ZAR
- Settlement negotiations collapse
- FDA approvals for pipeline drugs fall short
6/10
Johnson & Johnson is experiencing strong performance with stock up 28% YTD, driven by FDA clearance for its Ottava surgical robot, 64 consecutive years of dividend increases, and $100 billion revenue target. Most significantly, the company reached a proposed $5.5 billion settlement to resolve thousands of talc-related lawsuits, potentially eliminating a major legal risk. The company maintains resilience through diversified products and continues innovation with new drug approvals.
Our take is based on reporting first published by The Motley Fool.